Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In...

Area of Science:

• Immunodermatology
• Hematology
• Inflammation Research

Background:

• Whole blood cell counts and derived indices serve as indicators of inflammatory processes in diseases like psoriasis.
• Systemic therapies, particularly anti-IL-23 agents, show potential for anti-inflammatory and disease-modifying effects in psoriasis, though conclusive data is limited.

Purpose of the Study:

• To evaluate the therapeutic impact of risankizumab on whole blood cell counts and inflammatory indices in patients with psoriasis.
• To analyze the correlation between changes in hematological parameters and psoriasis disease severity during risankizumab therapy.

Main Methods:

• A prospective, multicenter observational study involving adult patients with moderate-to-severe psoriasis treated with risankizumab for at least 52 weeks.
• Monitoring of blood cell counts, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) at regular intervals up to week 52.
• Calculation and comparison of peripheral blood cell ratios (e.g., NLR, PLR, SII) at baseline and various time points (weeks 12, 24, 52) to assess treatment response.

Main Results:

• A consistent decrease in inflammatory markers (CRP, ESR, NLR, SII) was observed during risankizumab treatment.
• Significant reductions in neutrophils and mean platelet volume (MPV), alongside a transient increase in eosinophils and a progressive rise in basophils, were associated with treatment response.
• The most pronounced anti-inflammatory effects were noted in patients exhibiting a very early and near-complete response to risankizumab.

Conclusions:

• Risankizumab demonstrates a progressive anti-inflammatory effect in psoriasis patients.
• The anti-inflammatory benefits of risankizumab are more pronounced in individuals who achieve a rapid response early in the treatment course.